Insider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells 50,000 Shares of Stock

Posted by Stacy Sanders on Jul 3rd, 2024

Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) EVP Valerie Morisset sold 50,000 shares of the company’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $6.76, for a total value of $338,000.00. Following the sale, the executive vice president now directly owns 462,956 shares of the company’s stock, valued at $3,129,582.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eliem Therapeutics Price Performance

NASDAQ ELYM traded up $0.05 on Wednesday, hitting $6.86. 85,415 shares of the company were exchanged, compared to its average volume of 479,985. Eliem Therapeutics, Inc. has a twelve month low of $2.35 and a twelve month high of $11.55. The firm has a market capitalization of $204.10 million, a P/E ratio of -12.81 and a beta of -0.33. The company’s 50 day moving average price is $7.76 and its 200-day moving average price is $4.61.

Eliem Therapeutics (NASDAQ:ELYM – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.06) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Eliem Therapeutics stock. Cerity Partners LLC bought a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned approximately 0.05% of Eliem Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 69.76% of the company’s stock.

About Eliem Therapeutics

(Get Free Report)

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.